Literature DB >> 7613099

Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers.

H W Robbe1, J F O'Hanlon.   

Abstract

The effects of paroxetine (20 and 40 mg/day) and amitriptyline (75 mg/day, used as an active control) on car driving and psychomotor function were compared with those of placebo in a double-blind, crossover study employing 16 healthy subjects. Performance testing occurred on the first and last day of each 8-day treatment series. Side-effects, sleep duration and sleep quality were rated daily. Amitriptyline produced severe drowsiness and strikingly impaired performance on nearly every test on the first day but its effects were practically gone after 1 week of treatment. Paroxetine 20 mg, the usual antidepressant dose, had no effect on performance. Paroxetine 40 mg did not affect road tracking but slightly impaired performance in some psychomotor tests in a persistent manner. Paroxetine had no effect on sleep following the 20 mg dose but reduced quality following the 40 mg dose. Side-effects that the administered drugs have in common were milder during paroxetine than amitriptyline treatment. However, some dose-related side-effects (e.g. nausea and delayed ejaculation) were only reported during paroxetine treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613099     DOI: 10.1016/0924-977x(94)00130-4

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  20 in total

1.  Prescription of antidepressants and the risk of road traffic crash in the elderly: a case-crossover study.

Authors:  Ludivine Orriols; Machelle Wilchesky; Emmanuel Lagarde; Samy Suissa
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

2.  Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings.

Authors:  D S Veldhuijzen; J L Kenemans; A J M van Wijck; B Olivier; C J Kalkman; E R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

3.  Nefazodone. Psychomotor and cognitive effects.

Authors:  M W van Laar
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

5.  Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.

Authors:  Tim R M Leufkens; Annemiek Vermeeren; Beitske E Smink; Peter van Ruitenbeek; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

6.  Depression, antidepressants, and accidents.

Authors:  J G Edwards
Journal:  BMJ       Date:  1995-10-07

Review 7.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 8.  The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review : 70th Birthday Prof. Riederer.

Authors:  Alexander Brunnauer; Gerd Laux
Journal:  J Neural Transm (Vienna)       Date:  2012-06-09       Impact factor: 3.575

9.  The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men.

Authors:  M Siepmann; S Krause; P Joraschky; M Mück-Weymann; W Kirch
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

10.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.